<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840056</url>
  </required_header>
  <id_info>
    <org_study_id>2021.082</org_study_id>
    <nct_id>NCT04840056</nct_id>
  </id_info>
  <brief_title>Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis</brief_title>
  <acronym>GIMA</acronym>
  <official_title>Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis - Application of Artificial Intelligence in Histology and Clinical Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are:&#xD;
&#xD;
        -  To identify clinical or histological factors associated with gastric cancer development&#xD;
           in patients with IM and AG&#xD;
&#xD;
        -  To establish a machine learning algorithm for prediction of future gastric cancer risks&#xD;
           and individual risk stratification in patient with IM and AG&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part retrospective study including a clinical data part and a pathology part. A&#xD;
      training cohort will be developed from approximately 70% of included cases. It will be&#xD;
      followed by a validation cohort with the remaining cases.&#xD;
&#xD;
      Clinical data will be collected retrospectively using the Clinical Data Analysis and&#xD;
      Reporting System (CDARS) and Clinical management System (CMS). A cluster-wide cohort (New&#xD;
      Territories East Cluster, NTEC) consisting of patients with history of histologically-proven&#xD;
      gastric IM and AG will be identified and included for subsequent analysis. The data&#xD;
      collection period for the retrospective data will be 2000-2020.&#xD;
&#xD;
      Histology slides will be retrieved retrospectively when available (within NTEC). Whole slide&#xD;
      imaging technique will be utilized for the development of training and validation cohorts&#xD;
      with machine learning algorithms in the pathology part.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">September 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric cancer and gastric dysplasia</measure>
    <time_frame>20 years</time_frame>
    <description>The primary endpoint is the incidence of gastric cancer (intestinal-type) and gastric dysplasia (low grade and high grade dysplasia).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall accuracy of machine learning model</measure>
    <time_frame>20 years</time_frame>
    <description>Overall accuracy of machine learning models will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of machine learning model</measure>
    <time_frame>20 years</time_frame>
    <description>Sensitivity of machine learning model will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of machine learning model</measure>
    <time_frame>20 years</time_frame>
    <description>Specificity of machine learning model will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of machine learning model</measure>
    <time_frame>20 years</time_frame>
    <description>Positive predictive value of machine learning model will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of machine learning model</measure>
    <time_frame>20 years</time_frame>
    <description>Negative predictive value of machine learning model will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the receiver operating characteristic curve of machine learning model</measure>
    <time_frame>20 years</time_frame>
    <description>Area under the receiver operating characteristic curve of machine learning model will be evaluated</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Intestinal Metaplasia</condition>
  <condition>Atrophic Gastritis</condition>
  <arm_group>
    <arm_group_label>Intestinal Metaplasia</arm_group_label>
    <description>patient with history of histologically proven gastric intestinal metaplasia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrophic gastritis</arm_group_label>
    <description>patient with history of histologically proven atrophic gastritis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Clinical data will be collected retrospectively using the Clinical Data Analysis and&#xD;
        Reporting System (CDARS) and Clinical management System (CMS). A cluster-wide cohort (New&#xD;
        Territories East Cluster, NTEC) consisting of patients with history of&#xD;
        histologically-proven gastric IM and AG will be identified and included for subsequent&#xD;
        analysis. The data collection period for the retrospective data will be 2000-2020.&#xD;
&#xD;
        Histology slides will be retrieved retrospectively when available (within NTEC). Whole&#xD;
        slide imaging technique will be utilized for the development of training and validation&#xD;
        cohorts with machine learning algorithms in the pathology part.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults &gt;= 18 years of age&#xD;
&#xD;
          -  Histologically proven atrophic gastritis or intestinal metaplasia (at antrum and/or&#xD;
             body and/or angular of stomach)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Felix Sia</last_name>
    <phone>+85226370428</phone>
    <email>felix.sia@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thoma Lam</last_name>
    <phone>+85226370428</phone>
    <email>thomas.lam@cuhk.edu.hk</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Louis Ho Shing Lau</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>artificial intelligence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

